and pharmaceutically acceptable salts thereof

wherein

n is 1 or 2;

A is hydrogen, C_{1-6} alkyl, aryl, $-SO_2R^1$, $-PO(OC_{1-6}$ alkyl$)_2$, $-PO(C_{1-6}$ alkyl$)_2$, $-CO(C_{1-6}$ alkyl), $-CO_2R^2$, $-(CH_2)_mCO_2H$ or $-(CH_2)_mCO_2(C_{1-6}$ alkyl),

wherein

R^1 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, $-(CH_2)_m$aryl or $-NR^3R^4$

R^2 is C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, $-(CH_2)_m$aryl or alkenyl, and

m is 1, 2 or 3,

wherein

aryl is unsubsituted, substituted phenyl or 5-6 membered aromatic heterocyclic ring, and

R^3 and R^4 are independently hydrogen, C_{1-6} alkyl or C_{3-7} cycloalkyl;

B is hydrogen;

C and D are both

phenyl unsubsituted or substituted with one or two substituents selected from C_{1-4} alkyl, C_{1-4} alkoxy, methylenedioxy, halogen, hydroxy and NR^4R^5, or

C_{3-7} cycloalkyl;

E, F, and H are independently CR^5 or N and G is N,

wherein

R^5 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3, halogen, hydroxy or $-NR^3R^4$; and

I is $-C(NH)NH_2$, $-C(NH_2)NOH$, or $-CH_2NH_2$.